Chinese guidelines on clinical application of antiphospholipid antibodies (2026 edition)

Antiphospholipid antibodies (aPLs) are a group of autoantibodies that target phospholipids and/or phospholipid-binding proteins. aPLs are serum markers for antiphospholipid syndrome (APS) and are crucial indicators for predicting risks and managing anticoagulant therapy in APS and aPLs related diseases. Developing clinical guidelines for aPLs in China can further standardize laboratory testing and improve the ability to interpret results, thereby playing a critical role in enhancing the diagnostic, treatment, and management capabilities of clinicians involved in APS. National Clinical Research Center for Rheumatic and Autoimmune Diseases, collaborating with Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, China Rheumatism Data Center, Chinese Systemic Lupus Erythematosus Treatment and Research Group, strictly adhering to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system and the reporting items for practice guidelines in Healthcare (RIGHT) checklists. This guideline includes 10 recommendations on the clinical application of aPLs, aiming to standardize their clinical use and laboratory testing, and to provide references for the clinical diagnosis, treatment, and management of APS and aPLs related diseases.

抗磷脂抗体（aPLs）是一组以磷脂和/或磷脂结合蛋白为靶抗原的异质性自身抗体。aPLs是抗磷脂综合征（APS）诊断的血清标志物，亦是APS风险预测及抗凝治疗的重要评估指标。制订我国aPLs临床应用指南，可进一步规范aPLs实验室检测及提升结果解读能力，有助于提高APS诊疗水平。因此，风湿与自身免疫性疾病国家临床医学研究中心组织发起，联合风湿免疫病学教育部重点实验室、国家风湿病数据中心、中国系统性红斑狼疮研究协作组，严格遵循推荐意见分级的评估、制订及评价（GRADE）证据分级体系和国际实践指南报告标准（RIGHT），制订本指南。指南凝炼10条循证推荐意见，旨在规范aPLs临床应用及实验室检测，以期为APS及aPLs相关疾病临床诊疗和临床管理提供参考。.